As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
A nascent but growing consumer market for brain-computer interface technology is driving the development of sleek new tools for decoding brain activity.